Risk factors for acquisition of ventilator-associated pneumonia in adult intensive care units

Fariba Lahoorpour¹, Ali Delpisheh², Abdorrahim Afkhamzadeh³

ABSTRACT

Objective: Ventilator Associated Pneumonia (VAP) has an imperative place amongst nosocomial infections leading to increase morbidity and mortality rates. The present study aimed to determine risk factors for acquisition of ventilator- associated pneumonia in an intensive care unit (ICU).

Methods: A nested case-control study was carried out from September 2007 to June 2008. All 183 patients hospitalized at the adult ICU ward in Be’sat Hospital, Sanandaj city western Iran over a 48 hour period were included. Bacteriologic diagnosis and antibiotic susceptibility patterns were performed based on Edward & Ewing’s methods and CLSI system guidelines.

Results: Of the 149 samples which were taken from endotracheal tubes of 183 patients, 48 cases were diagnosed for VAP with an incidence rate of 26.2%. Mean duration of hospitalization was 23.4±10.2 days. The maximum and minimum antibiotic resistance for the gram negative bacteria was 93.3% for Cefalotin and 50% for Amikacin. The main risk factors for acquisition of ventilator- associated pneumonia were mechanical ventilation (Adjusted OR: 1.55, 95% CI: 1.37-1.74), history of antibiotic consumption (AOR: 8.92, CI: 1.16-66.66) and fever (AOR: 3.11, CI: 1.22-7.93).

Conclusions: VAP is significantly related to ICU hospitalization, mechanical ventilation and history of antibiotics consumption. Cefalotin and Amikacin showed the highest and lowest antibiotic resistance against gram negative bacteria respectively.

KEY WORDS: Ventilator-Associated Pneumonia (VAP), Intensive Care Unit.

doi: http://dx.doi.org/10.12669/pjms.295.3375

INTRODUCTION

Ventilator-associated pneumonia (VAP) occurs almost 48 hours after the initiation of endotracheal intubation and mechanical ventilation (MV).¹ The incidence of VAP varies from 9% to 60% of patients, based on the definition, type of hospital or ICU, study population and levels of antibiotic exposure. VAP is the main cause of nosocomial and acquired infections in ICUs.² Many predisposing factors including age and severity of the underlying diseases are associated with developing VAP. Meanwhile, history of antibiotic exposure and duration of mechanical ventilation are involved.³ VAP is also associated with considerable morbidity, including prolonged ICU hospitalization, extended mechanical ventilation and increased costs of hospitalization.⁴ Risk of VAP will be significantly increased up to 1-3% in intubated patients for each day requirement for mechanical ventilation.⁵,⁶
The present study aimed to determine ICU related bacteria and their antibiotic sensitivity and risk factors for acquisition of ventilator-associated pneumonia in an intensive care unit (ICU).

METHODS

Setting: The study was undertaken at the Be’sat teaching hospital in Sanandaj city, Kurdistan province western Iran. This hospital has an ICU with 12 beds.

Design: Through a nested case-control study, 149 eligible patients including 48 cases and 101 controls were included. Inclusion criteria were being adult over 15 years, hospitalized and being intubated and mechanically ventilated for more than 48 hours. The study was completed between September 2007 to June 2008.

Definitions: Pneumonia was considered ventilator associated when its onset occurred after 48 hours of mechanical ventilation and it was diagnosed when new, persistent pulmonary infiltrates appeared on chest radiographs along with at least two of following criteria: fever of ≥ 38°C, leukocytosis of 10,000 mm3 or more, and purulent respiratory secretions. In cases of clinically suspected pneumonia, endotracheal aspirate (EA) was performed early in the morning; and the diagnosis of VAP was established with a positive quantitative culture (a cut-off point of ≥106 CFU/ml was considered). To analyze the predisposing factors for development of VAP, the following variables were considered: age, gender, underlying diseases (diabetes mellitus, COPD and infection on admission), diagnosis besides total ICU hospitalization, antibiotic therapy and length of mechanical ventilation.

Statistical Analysis: Univariate analysis was used to compare variables for the outcomes of interest. Continuous data were compared using the Student’s t test. Either χ2 or Fisher’s exact tests were used to compare categorical variables. A multivariate analysis was also performed using multiple logistic regressions with stepwise approach. All P values lower than or equal to 0.05 were considered statistically significant.

The study was approved by the Kurdistan University of Medical Sciences Ethical Committee. An informed consent was obtained from each patient.

RESULTS

Of the 149 samples from endotracheal tube of 183 patients who were hospitalized in the adult ICU, 48 VAP cases were diagnosed with an incidence rate of 32.2%. Microorganisms responsible of VAP isolated from endotracheal tube were essentially Enterobacteriaceae (81.3%) with the head Klebsiella spp and isolates of Acinetobacter spp, Staphylococcus Epidermidis, Pseudomonas spp. and Staphylococcus aureus were 3, 3, 2, and 1 respectively. The maximum and minimum of antibiotic resistance against gram negative bacteria were 93.3% for Cefalotin and 50% for Amikacin.

Mean duration of hospitalization ± standard deviation was 23.39 ± 10.16 days. The mean interval between intubation, admission to the ICU, hospital admission and VAP identification were 3.7, 4.1, and 6.5 days, respectively. The main risk factors of VAP were mechanical ventilation (Adjusted OR: 1.55, 95% CI: 1.37-1.74), history of antibiotic exposure (AOR: 8.92, CI: 1.16-66.66) and fever (AOR: 3.11, CI: 1.22-7.93) as shown in Table-I.

DISCUSSION

The present study seems to be representative based on the nested case-control design and considerable sample size. The incidence rate of VAP was estimated to be 26.23 per 100 admitted patients and 32.2 per 100 ventilated patients. A corresponding rate of 7.16 per 100 admitted patients and 50 per 100 ventilated patients have already been reported in Senegal.7 An incidence rate of 22.6 per 1000 ventilator days has also been reported in Istanbul, Tureky.8 An Italian study has reported an incidence rate of 36.9 per1000 ventilator days.9

Table-I: Risk factors of acquisition of ventilator-associated pneumonia in an adult ICU in Kurdistan-Iran.

| VAP, n (%) | No (Controls) | Yes (Cases) | P value |
|-----------|---------------|-------------|---------|
| Patient’s gender | Male | 94 (70.7) | 39 (29.3) | 0.13 |
| | Female | 41 (82) | 9 (18) | |
| Antibiotic exposure | Yes | 116 (71.2) | 47 (28.8) | 0.03 |
| | No | 19 (95) | 1 (5) | |
| Fever | Yes | 93 (66.4) | 47 (33.6) | <0.000 |
| | No | 42 (97.7) | 1 (2.3) | |
| Duration of hospitalization | Yes | 28 (100) | 0 | <0.000 |
| | No | 107 (69) | 48 (31) | |
| Age groups (year) | 15-20 | 14 (87.5) | 2 (12.5) | 0.42 |
| | 21-40 | 64 (70.3) | 27 (29.7) | |
| | 41-60 | 21 (67.7) | 10 (32.3) | |
| | 61-80 | 30 (76.9) | 9 (23.1) | |

VAP: Ventilator-associated Pneumonia.
The mean intervals between intubation, admission to the ICU, hospital admission and the VAP identification in the present study were 3.7, 4.1, and 6.5 days respectively. This is comparable with a recent report of 3.3, 4.5, and 5.4 days in the United State.10

In the present study, the infection was polymicrobial. In a recent study conducted by Combes and colleagues, the ICU mortality rate, duration of MV and rate of infection relapse were not significantly affected by monomicrobial and polymicrobial VAP.11

The independent significant risk factors for acquisition of VAP in present study were mechanical ventilation, antibiotic exposure, duration of hospitalization and fever. These findings are consistent with a Nicaraguan study in which fever and duration of hospitalization were associated with acquisition of VAP12, and with the Baran’s study in which nosocomial infection was related to duration of hospitalization.13 Earlier similar findings have been reported.14,15 However, unlike the present study, it has shown that the independent risk factors for late versus early VAP acquired in ICU was advanced age.16

A recent case-control study showed that inappropriate initial antibiotic treatment was independently associated with relapse of VAP.6 Adequacy of antimicrobial therapy, duration of mechanical ventilation and duration of ICU hospitalization have already been reported to be associated with VAP.7-21

In conclusion, VAP is significantly related to ICU hospitalization, mechanical ventilation and history of antibiotics consumption. The maximum and minimum of antibiotic resistance against gram negative bacteria were 93.3 % for Cefalotin and 50 % for Amikacin.

**Grant Support:** Deputy of Research Affairs, Kurdistan University of Medical Sciences, Iran.

**REFERENCES**

1. Joseph NM, Sistla S, Dutta TK, Badhe AS, Parija SC. Ventilator-associated pneumonia in a tertiary care hospital in India: incidence and risk factors. J Infect Dev Ctries. 2009;3(10):771-777.

2. Katherasan SG, Naing L, Jalam K, Musa KD, Ntik Mohamad NA, Aiyr S, et al. Ventilator-associated nosocomial pneumonia in intensive care units in Malaysia. J Infect Dev Ctries. 2009;3(9):704-710.

3. Da Silva JM Jr, Rezende E, Guimaraes T, dos Campos EV, Magno LA, Consorti L, et al. Epidemiological and microbiological analysis of ventilator-associated pneumonia patients in a public teaching hospital. Braz J Infect Dis. 2007;11(5):482-488.

4. Rea-Neto A, Youssuf NCM, Tuche F, Brunnhorst F, Ranieri VM, Reinhard K, et al. Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care. 2008;12(2):1-14.

5. Apostolopoulos E, Bakakos P, Katostaras T, Gregorakos L. Incidence and risk factors for ventilator-associated pneumonia in 4 multidisciplinary intensive care units in Athens, Greece. Respir Care. 2003;48(7):681-688.

6. Nseir S, Favory R, Jozefowicz E, Decamps F, Dewavrin F, Brunin G, et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: A randomized, controlled, multicenter study. Crit Care. 2008;12(3):1-12.

7. Daif E, Beye MD, Ngoye MD, Kane O, Seydi AA, Ndaiye PI, et al. Nosocomial ventilator-associated pneumonia in a tropical intensive care unit. Dakar Med. 2006;51(2):81-88.

8. Erdem I, Ozgultekin A, Inan AS, Dincer E, Turan C, Ceron N, et al. Incidence, etiology and antibiotic resistance patterns of gram-negative microorganisms isolated from patients with ventilator-associated pneumonia in a medical-surgical intensive care unit of a teaching hospital in Istanbul, Turkey (2004-2006). Jpn J Infect Dis. 2006;61(5):339-342.

9. Prospero E, Bacelli S, Barbadoro P, Nataloni S, D’Errico MM, Pelaia P. Improvement of the ventilator associated pneumonia rate with infection control practices in an Italian ICU. Minerva Anestesiol. 2008;74(10):537-541.

10. Rello J, Ollendorf DA, Oster G, Vera-Lloch M, Bellm L, Redman R, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122(6):2115-2121.

11. Combes A, Figliolini C, Trouillet JL, Kassis N, Wolff M, Gibert C, et al. Incidence and outcome of polymicrobial ventilator-associated pneumonia. Chest. 2002;121(5):1618-1623.

12. Broughton EI, Lopez SR, Aguilar MN, Somarriba MM, Perez M, Sanchez N. Economic analysis of a pediatric ventilator-associated pneumonia prevention initiative in nicaragua. Int J Pediatr. 2012;2012:359430. doi: 10.1155/2012/359430. Epub 2012 Feb 8.

13. Baran G, Erbay A, Bodur H. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008;12(1):16-21.

14. Tennant I, Harding H, Nelson M. Microbial isolates from patients in an intensive care unit, and associated risk factors. West Indian Med J. 2005;54(4):225-231.

15. Rocha Lde A, Vilela CA, Cezario RC, Almeida AB, Filho PG. Ventilator-associated pneumonia in an adult clinical-surgical intensive care unit of a Brazilian university hospital: incidence, risk factors, etiology and antibiotic resistance. Braz J Infect Dis. 2008;12(1):80-85.

16. Giard M, Lepape A, Allaichiche B. Early and late –onset ventilator-associated pneumonia acquired in the intensive care unit; Comparison of risk factor. J Crit Care. 2008;23(1):27-33.

17. Teixeira PJ, Seligman R, Hertz FT. Inadequate treatment of ventilator-associated pneumonia; Risk factors and impact on outcomes. J Hospital Infect. 2007;65:361-367.

18. Rodrigues PM, Neto EC, Santos LR, Knibel MF. Ventilator-associated pneumonia: epidemiology and impact on the clinical evolution of ICU patients. J Bras Pneumol. 2009;35(11):1084-1091.

19. Aybar Turkoglu M, Issit AT. Ventilator-associated pneumonia caused by high risk microorganisms: a matched case-control study. Tuberk Toraks. 2008;56(2):139-149.

20. Moreira MR, Cardoso RL, Almeida AB, Gentijo Filho PP. Risk factors and evolution of ventilator-associated pneumonia by Staphylococcus aureus sensitive or resistant to oxacillin in patients at the intensive care unit of a Brazilian university hospital. Braz J Infect Dis. 2008;12(6):499-503.

21. Depuydt PO, Vandijck DM, Bekaert MA, Decruyenaere JM, Blot SI, Vogelaers DP, et al. Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia. Crit Care. 2008;12(6):R142. Epub 2008 Nov 17.

**Authors Contributions:**

FL: Study design, participating in manuscript writing and editing of manuscript. AD: Participating in manuscript writing and editing of manuscript. AA: Statistical analysis, manuscript writing, review and final approval of manuscript.